ABSTRACTS Abstracts Presented at the 10th Annual Meeting of the North American Neuroendocrine Tumor Society, October 19–21, 2017, Philadelphia, Pennsylvania therapy, and no prior exposure to a pyrrolobenzodiazepine-based drug. A 3+3 dose Immune Checkpoint Markers in Pulmonary Large Cell escalation is used in each cohort, at doses 0.2-0.4 mg/kg of Rova-T administered Neuroendocrine Carcinomas intravenously on Day 1 of each 42-day cycle, and proceeding until a maximum tolerated dose (MTD) is determined. A 2-stage design will be used for disease- Nagla Abdel Karim, Arun Sendilnathan, Ihab Eldessouki, Melissa Orr-Asman, specific expansion cohorts. Changchun Xie, Jiang Wang, Hala Elnakat Thomas. University of Cincinnati, Results: As of 3 April 2017, 31 pts (2 melanoma, 2 MTC, 3 GBM, 3 LCNEC, Cincinnati, OH. 3 NEPC, 3 GEP NEC, 10 other NEC, 5 other solid tumor) have been treated (26 Background: The overall prognosis for pulmonary large cell neuroendocrine pts at 0.2 mg/kg, 5 pts at 0.3 mg/kg Rova-T). MTD has not been reached. carcinoma (LCNEC) patients is poor despite treatment with front line systemic Twenty-six pts (84%) had an adverse event (AE), and only 3/31 pts (10%) chemotherapy regimens for small cell lung cancer (SCLC) or non-SCLC had a Grade 3+ AE
Pancreas – Wolters Kluwer Health
Published: Jan 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud